Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Phase 3

Completed

Conditions: Myelofibrosis

Interventions: Drug: Best Available Therapy (BAT)
Drug: Ruxolitinib

First Posted Date: 2009-07-08

Last Posted Date: 2019-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 219

Registration Number: NCT00934544

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren

First Posted Date: 2009-07-07

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT00933920

Locations: 🇮🇳
Novartis Investigative Site, New Delhi, India
🇮🇳
Novartis Investigator Site, Mangalore, India

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Phase 2

Terminated

Conditions: Post-Polycythemia Vera
Post-Essential Thrombocytopenia
Primary Myelofibrosis

Interventions: Drug: Panobinostat

First Posted Date: 2009-07-02

Last Posted Date: 2021-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT00931762

Locations: 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States

and more 6 locations

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Biological: Placebo
Biological: VAK694
Drug: Fluticasone

First Posted Date: 2009-06-30

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT00929968

Locations: 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇨🇦
Novartis Investigative Site, Ottawa, Ontario, Canada

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Secukinmab
Drug: Placebo

First Posted Date: 2009-06-26

Last Posted Date: 2015-10-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 237

Registration Number: NCT00928512

Locations: 🇨🇳
Novartis Investigative Site, Taichung, Taiwan

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Nateglinide 120 mg
Drug: Acarbose 50 mg

First Posted Date: 2009-06-26

Last Posted Date: 2012-05-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 160

Registration Number: NCT00928889

Locations: 🇨🇳
Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University, Guangzhou, China
🇨🇳
Peiking University First Hospital, BeiJing, China
🇨🇳
People's Liberation Army. The Military General Hospital of BeiJing, BeiJing, China

and more 3 locations

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Phase 2

Completed

Conditions: Gouty Arthritis

Interventions: Drug: Canakinumab

First Posted Date: 2009-06-25

Last Posted Date: 2021-07-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 341

Registration Number: NCT00927810

Locations: 🇬🇧
Novartis Investigative site, Jarrow, Tyne & Wear, United Kingdom

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol maleate 400 μg
Drug: Indacaterol acetate 400 μg
Drug: Indacaterol xinafoate 400 μg
Drug: Placebo to indacaterol

First Posted Date: 2009-06-25

Last Posted Date: 2013-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT00927901

Locations: 🇮🇹
Novartis Investigative Site, Verona, Italy

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: aliskiren
Drug: ramipril
Drug: Placebo to aliskiren
Drug: Placebo to ramipril

First Posted Date: 2009-06-18

Last Posted Date: 2012-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 123

Registration Number: NCT00923156

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
🇷🇺
Novartis Investigator Site, Moscow, Russian Federation

Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Biological: AIN457
Drug: prednisolone

First Posted Date: 2009-06-15

Last Posted Date: 2010-04-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00920933

Locations: 🇩🇪
Novartis Investigative Site, Grosshansdorf, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy